TRACON PHARMACEUTICALS INC's ticker is TCON and the CUSIP is 89237H209. A total of 25 filers reported holding TRACON PHARMACEUTICALS INC in Q4 2023. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2024 | $129 | +658.8% | 300,238 | +206.2% | 0.00% | – |
Q4 2023 | $17 | -29.2% | 98,038 | -27.1% | 0.00% | – |
Q3 2023 | $24 | -42.9% | 134,538 | -6.2% | 0.00% | – |
Q2 2023 | $42 | -86.8% | 143,484 | -14.9% | 0.00% | – |
Q1 2023 | $319 | +58.7% | 168,600 | +24.8% | 0.00% | – |
Q4 2022 | $201 | -99.8% | 135,049 | +98.9% | 0.00% | – |
Q3 2022 | $113,000 | +7.6% | 67,900 | +29.1% | 0.00% | – |
Q2 2022 | $105,000 | +36.4% | 52,600 | +80.1% | 0.00% | – |
Q1 2022 | $77,000 | -86.8% | 29,200 | -86.2% | 0.00% | -100.0% |
Q4 2021 | $584,000 | -50.8% | 211,000 | -31.3% | 0.00% | -50.0% |
Q3 2021 | $1,188,000 | +5.5% | 306,976 | +76.9% | 0.00% | +100.0% |
Q2 2021 | $1,126,000 | -43.1% | 173,535 | -27.9% | 0.00% | -50.0% |
Q1 2021 | $1,980,000 | +0.1% | 240,600 | +42.3% | 0.00% | 0.0% |
Q4 2020 | $1,978,000 | +369.8% | 169,100 | +107.5% | 0.00% | – |
Q3 2020 | $421,000 | -22.6% | 81,500 | -70.6% | 0.00% | – |
Q2 2020 | $544,000 | +38.1% | 277,396 | +19.7% | 0.00% | – |
Q1 2020 | $394,000 | +11.0% | 231,729 | +52.9% | 0.00% | – |
Q4 2019 | $355,000 | – | 151,529 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Opaleye Management Inc. | 4,190,000 | $6,997,000 | 2.89% |
Ikarian Capital, LLC | 2,765,530 | $4,618,000 | 0.92% |
Telemetry Investments, L.L.C. | 97,000 | $162,000 | 0.21% |
ACT CAPITAL MANAGEMENT, LLC | 28,500 | $48,000 | 0.07% |
JOHNSON & JOHNSON | 84,003 | $140,000 | 0.04% |
NEA Management Company, LLC | 346,719 | $579,000 | 0.03% |
X-Square Capital, LLC | 17,973 | $30,000 | 0.02% |
BOOTHBAY FUND MANAGEMENT, LLC | 258,844 | $432,000 | 0.01% |
LINDEN ADVISORS LP | 454,916 | $760,000 | 0.01% |
DOWLING & YAHNKE LLC | 47,455 | $79,000 | 0.00% |